hVIVO plc (LON:HVO - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 10.49 ($0.14) and traded as high as GBX 10.50 ($0.14). hVIVO shares last traded at GBX 10.23 ($0.14), with a volume of 913,857 shares.
Wall Street Analysts Forecast Growth
HVO has been the subject of a number of research reports. Peel Hunt restated an "add" rating and set a GBX 21 target price on shares of hVIVO in a report on Tuesday, July 29th. Shore Capital restated a "buy" rating and set a GBX 35 target price on shares of hVIVO in a report on Tuesday, July 22nd. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of GBX 28.
Check Out Our Latest Research Report on hVIVO
hVIVO Stock Down 2.1%
The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market cap of £70.97 million, a price-to-earnings ratio of 4.14 and a beta of 0.97. The business's 50 day moving average is GBX 10.43 and its 200 day moving average is GBX 14.12.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Recommended Stories
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access